Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients

I. M. L. W. Keularts, S. Beguin, C. de Zwaan, H. C. Hemker*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    82 Downloads (Pure)


    Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity: inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.
    Original languageEnglish
    Pages (from-to)370-371
    Number of pages2
    JournalThrombosis and Haemostasis
    Issue number3
    Publication statusPublished - 1 Jan 1998

    Cite this